[1]
|
R. Siegel, E. Ward, O. Brawley and A. Jemal, “Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths,” CA: A Cancer Journal for Clinicians, Vol. 61, No. 4, 2011, pp. 212-236. doi:10.3322/caac.20121
|
[2]
|
H. K. Sanoff, D. J. Sargent, M. E. Campbell, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, et al., “Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741,” Journal of Clinical Oncology, Vol. 26, No. 35, 2008, pp. 5721-5727. doi:10.1200/JCO.2008.17.7147
|
[3]
|
A. Lievre, J. B. Bachet, D. Le Corre, V. Boige, B. Landi, J. F. Emile, et al., “KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer,” Cancer Research, Vol. 66, No. 8, 2006, pp. 3992-3995. doi:10.1158/0008-5472.CAN-06-0191
|
[4]
|
R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, et al., “Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 26, No. 10, 2008, pp. 1626-1634.
doi:10.1200/JCO.2007.14.7116
|
[5]
|
M. Peeters, T. J. Price, A. Cervantes, A. F. Sobrero, M. Ducreux, Y. Hotko, et al., “Randomized Phase III Study of Panitumumab with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared with FOLFIRI Alone as Second-Line Treatment in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 28, No. 31, 2010, pp. 4706-4713. doi:10.1200/JCO.2009.27.6055
|
[6]
|
J. Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, et al., “Randomized, Phase III Trial of Panitumumab with Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) versus FOLFOX4 Alone as First-Line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer: The PRIME Study,” Journal of clinical oncology, Vol. 28, No. 31, 2010, pp. 4697-4705. doi:10.1200/JCO.2009.27.4860
|
[7]
|
T. S. Maughan, R. A. Adams, C. G. Smith, A. M. Meade, M. T. Seymour, R. H. Wilson, et al., “Addition of Cetu- ximab to Oxaliplatin-Based First-Line Combination Chemotherapy for Treatment of Advanced Colorectal Cancer: Results of The Randomised Phase 3 MRC COIN Trial,” Lancet, Vol. 377, No. 9783, 2011, pp. 2103-2114.
doi:10.1016/S0140-6736(11)60613-2
|
[8]
|
K. M. Tveit, T. Guren, B. Glimelius, P. Pfeiffer, H. Sorbye, S. Pyrhonen, et al., “Phase III Trial of Cetuximab with Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study,” Journal of clinical oncology, Vol. 30, No. 15, 2012, pp. 1755-1762.
doi:10.1200/JCO.2011.38.0915
|
[9]
|
J. Taieb, T. S. Maughan, C. Bokemeyer, E. Van Cutsem, T. Brodowicz, G. Folprecht, et al., “Cetuximab Combined with Infusional 5-Fluorouracil/Folinic Acid (5-FU/FA) and Oxaliplatin in Metastatic Colorectal Cancer (mCRC): A Pooled Analysis of COIN and OPUS Study Data,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract 3574.
|
[10]
|
J. Metges, J. Raoul, N. Achour, O. Capitain, A. Gourlaouen, J. Ramee, et al., “PANERB Study: Panitumumab after Cetuximab-Based Regimen Failure,” Journal of Clinical Oncology, Vol. 28, No. 15, 2010, p. e14000.
|
[11]
|
R. C. Wadlow, A. F. Hezel, T. A. Abrams, L. S. Blaszkowsky, C. S. Fuchs, M. H. Kulke, et al., “Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab,” The Oncologist, Vol. 17, No. 1, 2012, pp. e27-e34.
|
[12]
|
M. W. Saif, K. Kaley, E. Chu and M. S. Copur, “Safety and Efficacy of Panitumumab Therapy after Progression with Cetuximab: Experience at Two Institutions,” Clinical Colorectal Cancer, Vol. 9, No. 5, 2010, pp. 315-318.
doi:10.3816/CCC.2010.n.046
|
[13]
|
D. Power, M. Shah, T. Asmis, J. Garcia and N. Kemeny, “Safety and Efficacy of Panitumumab Following Cetuximab: Retrospective Review of the Memorial Sloan-Kettering Experience,” Investigational New Drugs, Vol. 28, No. 3, 2010, pp. 353-360.
doi:10.1007/s10637-009-9268-y
|
[14]
|
E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, et al., “New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1),” European Journal of Cancer, Vol. 45, No. 2, 2009, pp. 228-247. doi:10.1016/j.ejca.2008.10.026
|
[15]
|
D. J. Sargent, C. H. Kohne, H. K. Sanoff, B. M. Bot, M. T. Seymour, A. de Gramont, et al., “Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data from Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 27, No. 12, 2009, pp. 1948-1955.
doi:10.1200/JCO.2008.20.2879
|
[16]
|
M. Peeters, S. Siena, E. Van Cutsem, A. Sobrero, A. Hendlisz, S. Cascinu, et al., “Association of Progression-Free Survival, Overall Survival, and Patient-Reported Outcomes by Skin Toxicity and KRAS Status in Patients Receiving Panitumumab Monotherapy,” Cancer, Vol. 115, No. 7, 2009, pp. 1544-1554. doi:10.1002/cncr.24088
|
[17]
|
D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, et al., “Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer,” New England Journal of Medicine, Vol. 351, No. 4, 2004, pp. 337-345.
doi:10.1056/NEJMoa033025
|
[18]
|
M. Yashiro, H. Qiu, T. Hasegawa, X. Zhang, T. Matsuzaki and K. Hirakawa, “An EGFR Inhibitor Enhances the Efficacy of SN38, an Active Metabolite of Irinotecan, in SN38-Refractory Gastric Carcinoma Cells,” British Journal of Cancer, Vol. 105, No. 10, 2011, pp. 1522-1532.
doi:10.1038/bjc.2011.397
|
[19]
|
J. Franko, Q. Shi, C. D. Goldman, B. A. Pockaj, G. D. Nelson, R. M. Goldberg, et al., “Treatment of Colorectal Peritoneal Carcinomatosis with Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841,” Journal of Clinical Oncology, Vol. 30, No. 3, 2011, pp. 263-267.
|
[20]
|
S. Tejpar, I. Celik, M. Schlichting, U. Sartorius, C. Bokemeyer and E. Van Cutsem, “Association of KRAS G13D Tumor Mutations with Outcome in Patients with Metastatic Colorectal Cancer Treated with First-Line Chemotherapy with or Without Cetuximab,” Journal of Clinical Oncology, Jun 25 2012 [Epub Ahead of Print].
|
[21]
|
C. Montagut, A. Dalmases, B. Bellosillo, M. Crespo, S. Pairet, M. Iglesias, et al., “Identification of a Mutation in the Extracellular Domain of the Epidermal Growth Factor Receptor conferring Cetuximab Resistance in Colorectal Cancer,” Nature Medicine, Vol. 18, No. 9, 2012, pp. 1445-1445. doi:10.1038/nm0912-1445b
|